These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 17542349

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
    Persiani S, D'Amato M, Makovec F, Tavares IA, Bishai PM, Rovati LC.
    Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
    [Abstract] [Full Text] [Related]

  • 3. Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses.
    Moore KH, Hussey EK, Shaw S, Fuseau E, Duquesnoy C, Pakes GE.
    Cephalalgia; 1997 Jun; 17(4):541-50. PubMed ID: 9209776
    [Abstract] [Full Text] [Related]

  • 4. Safety, tolerability, and pharmacokinetics of sumatriptan suppositories following single and multiple doses in healthy volunteers.
    Kunka RL, Hussey EK, Shaw S, Warner P, Aubert B, Richard I, Fowler PA, Pakes GE.
    Cephalalgia; 1997 Jun; 17(4):532-40. PubMed ID: 9209775
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor.
    Moore KH, Cass LM, Dallow N, Hardman TC, Jones A, Boyce M, Prince WT.
    Eur J Clin Pharmacol; 2001 Jun; 56(11):805-11. PubMed ID: 11294370
    [Abstract] [Full Text] [Related]

  • 6. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
    Taylor L, Gidal B, Blakey G, Tayo B, Morrison G.
    CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
    [Abstract] [Full Text] [Related]

  • 7. Dose linearity and steady state pharmacokinetics of the new antiparkinson agent budipine after oral administration.
    Bethke TH, Merz M, Zech K, Seiberling M, Hauschke D, Heinze H, Wurst W.
    Int J Clin Pharmacol Ther; 2001 Jun; 39(6):259-64. PubMed ID: 11430634
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity.
    Marzo A, Dal Bo L, Monti NC, Crivelli F, Ismaili S, Caccia C, Cattaneo C, Fariello RG.
    Pharmacol Res; 2004 Jul; 50(1):77-85. PubMed ID: 15082032
    [Abstract] [Full Text] [Related]

  • 9. Investigation of sarizotan's impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes: a combined cocktail trial.
    Krösser S, Neugebauer R, Dolgos H, Fluck M, Rost KL, Kovar A.
    Eur J Clin Pharmacol; 2006 Apr; 62(4):277-84. PubMed ID: 16525816
    [Abstract] [Full Text] [Related]

  • 10. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
    Vaughan D, Speed J, Medve R, Andrews JS.
    Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
    [Abstract] [Full Text] [Related]

  • 11. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C, Bujanover S, Kareht S, Rapoport AM.
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.
    Jenner P, Könen-Bergmann M, Schepers C, Haertter S.
    Clin Ther; 2009 Nov; 31(11):2698-711. PubMed ID: 20110012
    [Abstract] [Full Text] [Related]

  • 13. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial.
    Goetz CG, Damier P, Hicking C, Laska E, Müller T, Olanow CW, Rascol O, Russ H.
    Mov Disord; 2007 Jan 15; 22(2):179-86. PubMed ID: 17094088
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics and tolerability of sumatriptan after single-dose administration of a fixed-dose combination tablet of sumatriptan/naproxen sodium 85/500 mg followed two hours later by subcutaneous sumatriptan 4- or 6-mg injection: a randomized, open-label, three-period crossover study in healthy volunteers.
    Berges A, Walls C, Lener SE, McDonald SA.
    Clin Ther; 2010 Jun 15; 32(6):1165-77. PubMed ID: 20637969
    [Abstract] [Full Text] [Related]

  • 15. Safety, pharmacokinetics, and pharmacodynamics of CHF 3381, a novel N-methyl-D-aspartate antagonist, after single oral doses in healthy subjects.
    Tarral A, Dostert P, Guillevic Y, Fabbri L, Rondelli I, Mariotti F, Imbimbo BP.
    J Clin Pharmacol; 2003 Aug 15; 43(8):901-11. PubMed ID: 12953347
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
    Lim KS, Kim JR, Choi YJ, Shin KH, Kim KP, Hong JH, Cho JY, Shin HS, Yu KS, Shin SG, Kwon OH, Hwang DM, Kim JA, Jang IJ.
    Clin Ther; 2008 Oct 15; 30(10):1817-30. PubMed ID: 19014837
    [Abstract] [Full Text] [Related]

  • 17. Safety, tolerability and pharmacokinetics of trimebutine 3-thiocarbamoylbenzenesulfonate (GIC-1001) in a randomized phase I integrated design study: single and multiple ascending doses and effect of food in healthy volunteers.
    Paquette JM, Rufiange M, Iovu Niculita M, Massicotte J, Lefebvre M, Colin P, Telmat A, Ranger M.
    Clin Ther; 2014 Nov 01; 36(11):1650-64. PubMed ID: 25224876
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
    Krauwinkel W, van Dijk J, Schaddelee M, Eltink C, Meijer J, Strabach G, van Marle S, Kerbusch V, van Gelderen M.
    Clin Ther; 2012 Oct 01; 34(10):2144-60. PubMed ID: 23063375
    [Abstract] [Full Text] [Related]

  • 19. Multiple-dose pharmacokinetics confirm no accumulation and dose proportionality of the novel promotile drug tegaserod (HTF 919).
    Appel-Dingemanse S, Hirschberg Y, Osborne S, Pommier F, McLeod J.
    Eur J Clin Pharmacol; 2001 Mar 01; 56(12):889-91. PubMed ID: 11317476
    [Abstract] [Full Text] [Related]

  • 20. The pharmacokinetics and safety of single escalating oral doses of eletriptan.
    Shah AK, Harris SC, Greenhalgh C, Morganroth J.
    J Clin Pharmacol; 2002 May 01; 42(5):520-7. PubMed ID: 12017346
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.